Alexander Kreuter
Alexander Kreuter is an expert in Dermatology at HELIOS St. Elisabeth Klinik Oberhausen (Germany). As of October 2026, ScienceLeadR ranks Alexander Kreuter in the top 1% of experts worldwide for Sexually Transmitted Diseases and Scleroderma, Localized. Alexander Kreuter has authored 662 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 1 of them ongoing. SLR score: 1,992 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Infectiology - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2001 - 2026
Number : 662
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| [Focal epithelial hyperplasia-Heck's disease]. PMID 42754675 — focal epithelial hyperplasia, skin diseases, diagnosis, alphapapillomavirus, hyperplasia, mucous membrane, human papillomavirus viruses | Dermatologie (Heidelb) | 2026 | 0 |
| [Update on anal dysplasia and anal cancer]. PMID 42758211 — anus neoplasms, neoplasms, biopsy, skin diseases, diagnosis, therapeutics, history | Dermatologie (Heidelb) | 2026 | 0 |
| [Vaccine prevention of HPV-associated diseases]. PMID 42726205 — vaccines, uterine cervical neoplasms, neoplasms, skin diseases, vaccination, viruses, warts, alphapapillomavirus, wounds and injuries, human papillomavirus viruses | Dermatologie (Heidelb) | 2026 | 0 |
| [When condylomas are not condylomas-lymphangioma circumscriptum in a child]. PMID 42622859 — skin diseases, lymphangioma, child | Dermatologie (Heidelb) | 2026 | 0 |
| Lichen sclerosus. Part 1. Guideline of the DGG, DGGG, OEGGG and SGGG (S3-Level, AWMF Registry No. 013-105, July 2025. PMID 42592485 — registries, pregnancy, language, lichen sclerosus et atrophicus, signs and symptoms, lichens, diagnosis, therapeutics | Geburtshilfe Frauenheilkd | 2026 | 0 |
Clinical Studies 10
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Evaluation of efficacy and safety of Cemiplimab as first line treatment for advanced basal cell carcinoma (CEMI first) An open label single arm prospective phase II trial of the DeCOG network 2024-517647-31-00 — cells, safety, therapeutics, carcinoma, basal cell, carcinoma | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map